652985-94-9

Upstream product

• 34164-16-4 N-[2-(3,4-dimethoxyphenyl)ethyl]-2-chloropropanamide 
• 645405-18-1 4-chloro-5-hydroxy-2-(tetrahydro-2H-pyran-2-yl)-3(2H)-pyridazinone 
• 173206-12-7 4-chloro-5-methoxy-2-(tetrahydro-2H-pyran-2-yl)-3(2H)-pyridazinone 
• 173206-13-8 4,5-dichloro-2-(tetrahydro-2H-pyran-2-yl)-3(2H)-pyridazinone 
• 110-87-2 3,4-dihydro-2H-pyran 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 

Downstream Products

• 652985-95-0 7-(tetrahydro-2H-pyran-2-yl)-4-(3,4-dimethoxyphenethyl)-3-hydroxy-2-methyl-3,4-dihydro-2H-pyridazino[4,5-b][1,4]oxazine-8(7H)-one 

Relevant academic research and scientific papers

One-pot synthesis of pyridazino[1,4]oxazin-3-ones

Pyridazino[1,4]oxazin-3-ones were conveniently prepared in a one-pot condensation of N-substituted 2-chloroacetamides with various 5-chloro-pyridazin-6-ones via rearrangement of a spiro-aminoketal intermediate.

Synthetic studies on isoquinoline derivatives with multidrug resistance (MDR) modulating activity

Tetrahydropyridazino-1,4-oxazinoisoquinoline derivatives with multidrug Resist. (MDR) modulating activity were designed and synthesized. A key step for cyclization of 1,4-oxazine ring was developed using K2CO3 and CH3CN in one-pot. Among prepared compounds, 2-(4-fluorobenzyl)-9,10-dimethoxy-12-methyl-6,7,11b,12-tetrahydropyridazino[4', 5',5,6] [1,4]oxazine-[3,4,-a]isoquinolin-1(2H)-one (1f) exhibited significant MDR reversing activity and low toxicity, which might be as potential MDR agent.